Engineered immune cells take on rare protein disease in major trial
NCT ID NCT07709715
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 3 trial compares an experimental CAR-T cell therapy, NXC-201, with a standard drug combination (daratumumab plus CyBorD) in people newly diagnosed with AL amyloidosis, a rare condition where abnormal proteins damage organs. Participants receive either a single infusion of their own genetically modified immune cells or a course of standard medications. The study measures how well each approach controls the disease and prevents organ deterioration.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a CAR-T cell therapy called NXC-201, made from the patient's own immune cells
- What this could lead to
- If successful, NXC-201 could offer a more effective, one-time treatment option for people newly diagnosed with AL amyloidosis, potentially improving organ function and survival.
- What could go wrong
- This is an early-stage comparison against an existing therapy, and CAR-T therapies carry risks like cytokine release syndrome and neurological side effects. Long-term outcomes are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT CHAIN (AL) AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.